Iovance Biotherapeutics

Bewertungs-Analyse

Über das Unternehmen

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145

Trading-Daten

Ähnliche Aktien aus dem Sektor

Wo kann ich Iovance Biotherapeutics kaufen?

Vergleiche die besten Broker — niedrige Gebühren, seriöse Anbieter, reguliert.